[1]牟东,周德江,江忠勇,等.非酒精性脂肪性肝病患者肝组织水通道蛋白表达差异与多烯磷脂酰胆碱疗效相关性分析[J].第三军医大学学报,2017,39(18):1859-1864.
 MU Dong,ZHOU Dejiang,JIANG Zhongyong,et al.Expression difference of liver aquaporins and its correlation with curative effect of multiphosphatidycholine in nonalcoholic fatty liver disease patients[J].J Third Mil Med Univ,2017,39(18):1859-1864.
点击复制

非酒精性脂肪性肝病患者肝组织水通道蛋白表达差异与多烯磷脂酰胆碱疗效相关性分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第18期
页码:
1859-1864
栏目:
临床医学
出版日期:
2017-09-30

文章信息/Info

Title:
Expression difference of liver aquaporins and its correlation with curative effect of multiphosphatidycholine in nonalcoholic fatty liver disease patients
作者:
牟东周德江江忠勇陈备金张勇曾维政吴晓玲
成都军区总医院:消化内科, 检验科
Author(s):
MU Dong ZHOU Dejiang JIANG Zhongyong CHEN Beijin ZHANG Yong ZENG Weizheng WU Xiaoling

Department of Gastroenterology, Department of Clinical Laboratory, General Hospital of Chengdu Military Command , Chengdu, Sichuan Province, 610083, China

关键词:
水通道蛋白多烯磷脂酰胆碱非酒精性脂肪肝病
Keywords:
aquaporin polyene phosphatidylcholine nonalcoholic fatty liver disease
分类号:
R575.2;R589.2;R977.6
文献标志码:
A
摘要:

目的     分析非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)患者肝组织水通道蛋白 (aquaporin,AQPs)3、7、9表达水平对多烯磷脂酰胆碱(plyene posphatidyl coline, PPC)疗效的影响。方法      分析2014-2016年本院收治的NAFLD患者87例,按病程分组:肝硬化组(n=30), 肝纤维化组(n=24),肝炎组(n=33);超声疗效评估分组:有效组和无效组。随访不同病程的NAFLD患者PPC治疗前后的肝功能酶变化,按照PPC疗效进行分组,比较患者肝组织AQP3、7、9蛋白的表达差异, 并进一步分析PPC疗效与AQPs表达水平的相关性。结果PPC对NAFLD患者治疗整体有效率3563%,PPC对NAFLD疗效与病程严重程度无关,但与超声的评分密切相关, 表现为按照超声评分有效和无效分组的不同病程组患者的谷丙转氨酶(ALT)在PPC治疗后,在每种病程患者中差异有统计学意义,且ALT在PPC治疗后,其变化程度与超声的变化程度呈正相关,肝硬化组(R=0.780,P<0.01),肝纤维化组(R=0.879,P<0.01),肝炎组最高(R=0.900,P<0.01)。PPC治疗NAFLD效果与患者初始的肝组织AQPs的表达存在相关性: NAFLD患者肝组织AQP7、9表达量与肝功能酶的变化量呈正相关(AQP9: R=0.972, AQP7: R=0.537),而AQP3的表达水平与肝功能酶的变化量呈负相关(R=-0.881); AQP7、9表达量与超声评分的变化量呈正相关 (AQP9: R=0.763,AQP7: R=0.311),而AQP3的表达水平与肝功能酶的变化量呈负相关(R=-0.795)。结论     多烯磷脂酰胆碱对非酒精性脂肪性肝病的疗效与水通道蛋白表达差异密切相关,提示AQPs表达水平可能影响PPC疗效。

Abstract:

Objective      To determine the effect of expression levels of aquaporins (AQPs) 3, 7 and 9 on the therapeutic effect of multi-phosphatidycholine (PPC) in the patients with nonalcoholic fatty liver disease (NAFLD). Methods      A total of 87 NAFLD patients admitted in our hospital from 2014 to 2016 were recruited in this study. According to their courses of the disease, they were divided into cirrhosi (n=30), liver fibrosis (n=24), and hepatitis groups (n=33). After the treatment with PPC, ultrasonic examination was used to evaluate the effective and ineffective patients, and the changes of liver function enzymes were also observed. The expression levels of AQPs 3, 7 and 9 in the liver tissues were compared in the patients with different courses of NAFLD. The correlation between the effect of PPC and the expression levels of AQPs were analyzed. Results      The total effective rate of PPC was 35.63% in the NAFLD patients, and the effect of PPC on NAFLD was not related to the severity of the disease, but was closely related to the scores of ultrasound examination. Significant differences were found in ALT level between the PPC effective and ineffective patients, and among the patients with difference courses of NAFLD. What’s more, the ALT level was positively correlated with changes of ultrasound examination in the cirrhosi group (R=0.780, P<0.01), liver fibrosis group (R=0.879, P<0.01), and the hepatitis group (R=0.900, P<0.01). The effect of PPC on NAFLD was correlated with the initial expression levels of AQPs in the liver tissues. The levels of AQPs 7 and 9 were positively correlated with the changes of liver function ( AQP9: R= 0.972, AQP7: R=0.537 ), and that of AQP 3 was negatively correlated with the changes of liver function enzymes (R=-0.881); The expression levels of AQPs 7 and 9 were positively correlated with the change of ultrasonic score (AQP9: R=0.763, AQP7: R=0.311), and that of AQP 3 was negatively correlated with the change of liver function (R=-0.795). Conclusion      The effect of PPC on NAFLD is closely related to the expression levels of AQPs, suggesting that the levels may influence the effect of PPC.

参考文献/References:

[1]PARK S H, JEON W K, KIM S H, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 1): 138-143. DOI: 10.1111/j.14401746.2005.04086.x.
[2] FAN J G, FARRELL G C. Epidemiology of nonalcoholic fatty liver disease in China [J]. J Hepatol, 2009, 50(1): 204-10. DOI: 10.1016/j.jhep.2008.10.010
[3]MELO R, FIELDHOUSE R, MELO A, et al. A Machine Learning Approach for HotSpot Detection at ProteinProtein Interfaces [J]. Int J Mol Sci, 2016, 17(8): DOI: 10.3390/ ijms17081215
[4]TARDELLI M, MORENO-VIEDMA V, ZEYDA M, et al. Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state [J]. J Gastroenterol Hepatol, 2017 J,32(1): 253-260. DOI: 10.1111/jgh.13415.
[5]GU L Y, QIU L W, CHEN X F, et al. Oleic acidinduced hepatic steatosis is coupled with downregulation of aquaporin 3 and upregulation of aquaporin 9 via activation of p38 signaling[J]. Hormon-und Stoffwechselforschung = Hormones et metabolisme, 2015, 47(4): 259-264. DOI: 10.1055/s-0034-1384569.
[6]CAI C, WANG C, JI W, et al. Knockdown of hepatic aquaglyceroporin-9 alleviates high fat diet-induced non-alcoholic fatty liver disease in rats[J]. Int Immunopharmacol, 2013, 15(3): 550-556. DOI: 10.1016/ j.intimp.2013.01.020.
[7]GUO X, SUN T, YANG M, et al. Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma[J]. Biomed Res Int, 2013, 2013: 206525. DOI: 10. 1155/2013/206525.
[8]钱蕴秋. 超声诊断学[M]. 第2版. 西安: 第四军医大学出版社, 2008: 532.
QIAN Y Q. Diagnostic Medical Sonography. The second edition[M]. Xi’an: The Fourth Military Medical University Press. 2008: 532.
[9]苏红领, 朱玉侠, 高正军, 等. 双环醇与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较[J]. 中华肝脏病杂志, 2011, 19(7): 552-553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07. 019.
SU H L, ZHU Y X, GAO Z J, et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2011, 19(7): 552-553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07.019.
[10]李进,李月翠,胡伟跃,等.自拟降脂护肝方联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床研究[J]. 中华中医药学刊, 2015, 33(1): 236-239. DOI: 10.13193/j.issn.16737717. 2015.01.071.
LI J, LI Y C, HU W Y, et al. Clinical Research of SelfPrepared Decoction of Lipid-Decreasing and Liver Protection Combined Polyene Phosphatidylcholine for Treatment of Nonalcoholic Fatty Liver Disease[J]. Chin Arch Tradi Chin Med, 2015, 33(1): 236-239. DOI: 10.13193/j.issn.16737717.2015.01.071.
[11]刘梅, 陆伦根, 曾民德. 多烯磷脂酰胆碱对肝细胞保护机制的研究进展[J]. 肝脏, 2006, 11(1): 43-45. DOI: 10.3969/ j.issn.1008-1704.2006.01.016.
LIU M, LU L G, ZENG M D. Advances in the hepatocellulor protective machanisms of polyenylphosphatidylcholine[J]. Chin Hepatol, 2006, 11(1): 43-45. DOI: 10.3969/ j.issn.10081704.2006.01.016.
[12]KOYAMA Y, YAMAMOTO T, TANI T, et al. Expression and localization of aquaporins in rat gastrointestinal tract[J]. Am J Physiol, 1999, 276(3 Pt 1): C621-C627.
[13]ASHRAF Z, ALAMGEER, RASOOL R, et al. Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs [J].  Int J Mol Sci, 2016, 17(12). pii: E2151. DOI: 10.3390/ijms17122151.
[14]LAFORENZA U. Water channel proteins in the gastrointestinal tract[J]. Mol Aspects Med, 2012, 33(5-6): 642-650. DOI:10.1016/j.mam.2012.03.001.
[15]GREGOIRE F, LUCIDI V, ZERRADSAADI A, et al. Analysis of aquaporin expression in liver with a focus on hepatocytes[J]. Histochem Cell Biol, 2015, 144(4): 347-363. DOI: 10.1007/ s00418-015-1341-3.

更新日期/Last Update: 2017-09-29